Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

398 United States sites

155 India sites

125 United Kingdom sites

75 Canada sites

75 Italy sites

50 France sites

50 Spain sites

50 Turkey sites

49 Greece sites

25 South Africa sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease

The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD).

Locations

165 United States sites

78 Lebanon sites

76 United Kingdom sites

72 Greece sites

Age

18 Years - 60 Years

Phase

Phase 2

LEARN MORE
ESCORT-HU Extension: European Sickle Cell Disease Cohort – Hydroxyurea – Extension

As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.

Locations

1098 France sites

90 Germany sites

72 French Guiana sites

72 Italy sites

36 Guadeloupe sites

36 Martinique sites

18 Greece sites

Age

> 2 Years

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

1007 United States sites

133 United Kingdom sites

95 France sites

95 Spain sites

76 Greece sites

76 Italy sites

57 Canada sites

38 Lebanon sites

38 Germany sites

38 Oman sites

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE